Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies
Tóm tắt
The proteasome is responsible for the degradation of intracellular proteins, including several involved in cell cycle control and the regulation of apoptosis. Preclinical studies have shown that the proteasome inhibitor bortezomib decreases proliferation, induces apoptosis, enhances the activity of chemotherapy and radiation, and reverses chemoresistance in a variety of hematologic and solid malignancy models in vitro and in vivo. Proteasome inhibition with bortezomib has specifically promoted apoptosis of tumor cells through the stabilization of p53, p21, p27, Bax, and IκBα, resulting in nuclear factor κB inhibition. Bortezomib was the first proteasome inhibitor to enter clinical trials. In two Phase II trials, SUMMIT and CREST, it was found that treatment with bortezomib, alone or in combination with dexamethasone, produced durable responses with meaningful survival benefits in patients with recurrent and/or refractory multiple myeloma. In the APEX Phase III trial, bortezomib produced significant survival benefits and improved response rates over high‐dose dexamethasone at first recurrence and beyond in patients with multiple myeloma. Clinical trials evaluating the safety and activity of bortezomib alone or in combination regimens with dexamethasone, doxorubicin, melphalan, prednisone, and/or thalidomide in the treatment of patients with newly diagnosed multiple myeloma have shown encouraging results. Preliminary studies suggest that bortezomib may serve as induction therapy before stem cell transplantation. Proteasome inhibition with bortezomib also has shown activity with manageable toxicity in mantle cell and other lymphomas, leukemias, and solid malignancies, including nonsmall cell lung carcinoma. Further studies with bortezomib as monotherapy and in combination regimens in the treatment of solid and hematologic malignancies are warranted. Cancer 2005. © 2005 American Cancer Society.
Từ khóa
Tài liệu tham khảo
Adams J, 2003, The proteasome: structure, function, and role in the cell, Cancer Treat Rev., 29, 3‐9
Bedi A, 2000, Clinical oncology, 10
Waldman T, 1995, p21 is necessary for the p53‐mediated G1 arrest in human cancer cells, Cancer Res., 55, 5187
Voorhees PM, 2003, The proteasome as a target for cancer therapy, Clin Cancer Res., 9, 6316
Adams J, 1999, Proteasome inhibitors: a novel class of potent and effective antitumor agents, Cancer Res., 59, 2615
Ling YH, 2002, PS‐341, a novel proteasome inhibitor, induces Bcl‐2 phosphorylation and cleavage in association with G2‐M phase arrest and apoptosis, Mol Cancer Ther., 1, 841
Ling YH, 2003, Mechanisms of proteasome inhibitor PS‐341‐induced G(2)‐M‐phase arrest and apoptosis in human non‐small cell lung cancer cell lines, Clin Cancer Res., 9, 1145
Ma MH, 2003, The proteasome inhibitor PS‐341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents, Clin Cancer Res., 9, 1136
Hideshima T, 2001, The proteasome inhibitor PS‐341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells, Cancer Res., 61, 3071
LeBlanc R, 2002, Proteasome inhibitor PS‐341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model, Cancer Res., 62, 4996
Aghajanian C, 2002, A Phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies, Clin Cancer Res., 8, 2505
Berenson J, 2004, A Phase I/II trial of VELCADE and melphalan combination therapy (Vc+M) for patients with relapsed or refractory multiple myeloma (MM), Blood., 104, 64a
Hollmig K, 2004, Addition of bortezomib (Velcade™) to high dose melphalan (Vel‐Mel) as an effective conditioning regimen with autologous stem cell support in multiple myeloma (MM), Blood., 104, 266a, 10.1182/blood.V104.11.929.929
Chanan‐Khan A, 2004, A Phase II study of Velcade (V), Doxil (D) in combination with low‐dose thalidomide (T) as salvage therapy for patients (pts) with relapsed (rel) or refractory (ref) multiple myeloma (MM) and Waldenstrom's macroglobulinemia (WM): encouraging preliminary results, Blood., 104, 665a, 10.1182/blood.V104.11.2421.2421
Giralt S, 2004, Results of bortezomib (BTZ) therapy for myeloma (MM) patients relapsing after an allogeneic transplant, Blood., 104, 459a, 10.1182/blood.V104.11.1651.1651
Jagannath S, 2003, Phase II trials of bortezomib in combination with dexamethasone in multiple myeloma (MM): assessment of additional benefits to combination in patients with sub‐optimal responses to bortezomib alone, Proc Am Soc Clin Oncol., 22, 582
Richardson PG, 2004, Phase II trial of single agent bortezomib (VELCADE) in patients with previously untreated multiple myeloma (MM), Blood., 104, 100a, 10.1182/blood.V104.11.336.336
Harousseau J, 2004, Bortezomib (VELCADE®) plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: preliminary results of an IFM Phase II study, Blood., 104, 416a, 10.1182/blood.V104.11.1490.1490
Cavenagh J, 2004, PAD combination therapy (PS‐341/bortezomib, Adriamycin and dexamethasone) for previously untreated patients with multiple myeloma, Blood., 104, 413a, 10.1182/blood.V104.11.1478.1478
Alexanian R, 2004, VTD (Velcade, thalidomide, dexamethasone) as primary therapy for newly‐diagnosed multiple myeloma, Blood., 104, 64a
Mateos MV, 2004, A Phase I/II national, multicenter, open‐label study of bortezomib plus melphalan and prednisone (V‐MP) in elderly untreated multiple myeloma patients, Blood., 104, 943a, 10.1182/blood.V104.11.3462.3462
Gatto S, 2003, The proteasome inhibitor PS‐341 inhibits growth and induces apoptosis in Bcr/Abl‐positive cell lines sensitive and resistant to imatinib mesylate, Haematologica., 88, 853
Tan C, 2002, Proteasome inhibitor PS‐341, a potential therapeutic agent for adult T‐cell leukemia, Cancer Res., 62, 1083
Attar EC, 2004, Phase I dose escalating trial of bortezomib (VELCADE) in combination with idarubicin and cytarabine in patients with acute myeloid leukemia, Blood., 104, 498a, 10.1182/blood.V104.11.1799.1799
Faderl S, 2004, Phase 2 study of three doses of single agent bortezomib in patients with fludarabine‐refractory B‐cell CLL, Blood., 104, 293b, 10.1182/blood.V104.11.4841.4841
Chen CI, 2004, Antitumor activity of bortezomib (PS‐341; Velcade) in a Phase II study of patients with previously untreated or treated Waldenstrom's macroglobulinemia (WM), Blood., 104, 896a
Dunleavy K, 2004, Phase I/II study of bortezomib alone and bortezomib with dose‐adjusted EPOCH chemotherapy in relapsed or refractory aggressive B‐cell lymphoma, Blood., 104, 389a, 10.1182/blood.V104.11.1385.1385
Younes A, 2004, Safety and efficacy of bortezomib (Velcade) for the treatment of relapsed classical Hodgkin's disease, Blood., 104, 722a, 10.1182/blood.V104.11.2638.2638
Chauhan D, 2003, Blockade of Hsp27 overcomes bortezomib/proteasome inhibitor PS‐341 resistance in lymphoma cells, Cancer Res., 63, 6174
Williams S, 2003, Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts, Mol Cancer Ther., 2, 835
Sunwoo JB, 2001, Novel proteasome inhibitor PS‐341 inhibits activation of nuclear factor‐kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma, Clin Cancer Res., 7, 1419
Frankel A, 2000, Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS‐341, Clin Cancer Res., 6, 3719
Teicher BA, 1999, The proteasome inhibitor PS‐341 in cancer therapy, Clin Cancer Res., 5, 2638
Cusack JC, 2001, Enhanced chemosensitivity to CPT‐11 with proteasome inhibitor PS‐341: implications for systemic nuclear factor‐kappaB inhibition, Cancer Res., 61, 3535
Appleman LJ, 2003, Phase I dose escalation study with bortezomib and gemcitabine safety and tolerability in patients with advanced solid tumors, Proc Am Soc Clin Oncol., 22, 209a
Albanell J, 2003, Phase I study of bortezomib in combination with docetaxel in anthracycline‐pretreated advanced breast cancer, Proc Am Soc Clin Oncol., 22, 16
Fanucchi MP, 2004, Phase (ph) 2 study of bortezomib ± docetaxel in previously treated patients (pts) with advanced non‐small cell lung cancer (NSCLC). Preliminary results, J Clin Oncol., 22, 643s
Davies AM, 2004, The proteasome inhibitor, bortezomib, in combination with gemcitabine (gem) and carboplatin (carbo) in advanced non‐small cell lung cancer (NSCLC): final results of a phase I California Consirtium study, J Clin Oncol., 22, 642s
Stevenson J, 2004, Phase II/pharmacodynamic trial of PS‐341 (bortezomib, VELCADE®) in advanced non‐small cell lung cancer, J Clin Oncol., 22, 652s
Ryan DP, 2003, Phase I dose escalation study of the proteasome inhibitor, bortezomib, plus irinotecan in patients with advanced solid tumors, Proc Am J Clin Oncol., 22, 228
Millennium Pharmaceuticals, Inc., 2005, VELCADE (bortezomib) for injection
Lonial S, 2004, Evaluation of the severity and risk of thrombocytopenia with bortezomib therapy in relapsed and refractory multiple myeloma, Hematol J., 5, S130
Richardson PG, 2004, Characterization and reversibility of peripheral neuropathy in patients with advanced multiple myeloma treated with bortezomib (VELCADE), Hematol J., 5, S129